Can the adrenocortical cancer drug mitotane treat Cushing's syndrome?

The adrenocortical cancer drug Mitotane (Mitotan) can indeed treat Cushing's syndrome.

Mitotane (also known as mitotane) is a drug specially used to treat adrenocortical diseases. It has a significant effect on adrenocortical cancer and the Cushing's syndrome caused by it. It reduces cortisol production by inhibiting cholesterol side chain cleavage enzymes and interfering with key enzymes in adrenocortical hormone synthesis, such as 11β-hydroxylase and 17α-hydroxylase. In multiple clinical studies, mitotane has been shown to reduce cortisol levels in patients, effectively reduce tumor size, and relieve symptoms associated with Cushing's syndrome.

Cushing's syndrome is a disorder caused by excessive secretion of cortisol from the adrenal cortex. Mitotane treats Cushing's syndrome by inhibiting the function of the adrenal cortex and reducing cortisol secretion. Specifically, mitotane can inhibit the activity of adrenocortical cells. Mitotane can significantly reduce the secretion of cortisol, thereby alleviating the symptoms related to Cushing's syndrome.

The use of mitotane can significantly improve the clinical symptoms of patients with Cushing's syndrome, such as hypertension, moon face, buffalo hump, etc. Improvement of these symptoms can help improve patients' quality of life. By lowering cortisol levels, mitotane can also prevent various complications that may occur with Cushing's syndrome, such as cardiovascular disease and diabetes.

Although mitotane has shown significant efficacy in the treatment of Cushing's syndrome, it may also cause some adverse reactions, such as nausea, vomiting, diarrhea, etc. Therefore, it is necessary to pay close attention to the patient's response when using mitotane and adjust the treatment plan according to the patient's specific situation.

References:

https://www.sciencedirect.com/science/article/abs/pii/S1521690X20300427